Posted on 25th July, 2019
by Legal Staff
Nintedanib has been studied as a potential cure for mesothelioma for several years now, but recent research shows it does not entail any improvement of the disease in patients suffering from it.
In the article "The Future of Mesothelioma Treatment: Time to Shift Gears" published in the medical journal The Lancet Respiratory Journal, authors Michele Maio, MD, PhD and Luana Calabr, MD, PhD, both from the department of oncology, medical oncology and immunotherapy at the Center for Immuno-Oncology, University Hospital of Siena, Italy, are explaining the ineffectiveness of this medication in treating mesothelioma. In the study they conducted, they administered mesothelioma patients a combination of nintedanib, cisplatin and pemetrexed, which led to no improvement in the progression-free survival of the people with the disease. Additionally, the treatment does not help the quality of life either.
It was discovered that a great number of patients who were given nintedanib were experiencing very bothersome side-effects. "This latest failure of an anti-angiogenetic drug in patients with mesothelioma fosters consistent doubts and skepticism and raises the questions of whether we should drop the anti-angiogenetic approach after so many trial failures," said the authors conclusively.
However, despite nintedanib not being effective for alleviating malignant mesothelioma, people struggling with it still have a wide range of treatment available which they can try, either in the hospital or in clinical trials.
It has recently been revealed that a combination of surgery and chemotherapy is the most efficient treatment method for most mesothelioma patients.
Nevertheless, mesothelioma is a very complex disease and every patient requires personalized treatment in order to experience remission. Atraxia Law's mission is to make your life better by connecting you to trustworthy resources that ensure you come out on top, every time. We're here to help you find out if your mesothelioma case qualifies and you are eligible to receive compensation.